Spikevax (previously COVID-19 Vaccine Moderna)

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2

Available from:

Moderna Biotech Spain, S.L.

ATC code:

J07BN01

INN (International Name):

COVID-19 mRNA vaccine, elasomeran, elasomeran / imelasomeran, elasomeran / davesomeran, andusomeran

Therapeutic group:

Cepiva

Therapeutic area:

COVID-19 virus infection

Therapeutic indications:

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. Spikevax bivalent Original/Omicron BA. 1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against COVID-19. Spikevax bivalent Original/Omicron BA. 4-5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.  Spikevax XBB. 5 is indicated for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 6 months of age and older. The use of this vaccine should be in accordance with official recommendations.

Product summary:

Revision: 41

Authorization status:

Pooblaščeni

Authorization date:

2021-01-06

Patient Information leaflet

                                114
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v zamrzovalniku pri temperaturi od -50 °C do -15 °C.
Preberite navodilo za uporabo za informacije o roku uporabnosti po
prvem odprtju in dodatne
informacije o shranjevanju.
Vialo shranjujte v zunanji ovojnini za zagotovitev zaščite pred
svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
MODERNA BIOTECH SPAIN, S.L.
C/ Julián Camarillo nº 31
28037 Madrid
Španija
_ _
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/20/1507/001
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
_ _
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
115
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
116
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
NALEPKA NA VEČODMERNI VIALI
1.
IME ZDRAVILA IN POT(I) UPORABE
Spikevax 0,2 mg/ml disperzija za injiciranje
mRNK cepivo proti COVID-19
elasomeran
i.m.
2.
POSTOPEK UPORABE
intramuskularna uporaba
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
večodmerna viala
5 ml
6.
DRUGI PODATKI
Za navodilo za uporabo optično preberite kodo ali obiščite
www.modernacovid19global.com.
Datum/čas zavrženja cepiva:
117
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA (VEČODMERNA VIALA)
1.
IME ZDRAVILA
Spikevax 0,1 mg/ml disperzija za injiciranje
mRNK cepivo proti COVID-19
elasomeran
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena večodmerna viala vsebuje 2,5 ml.
_ _
En odmerek (0,5 ml) vsebuje 50 mikrogramov elasomerana. En
odmerek (0,25 ml) vsebuje 25 mikrogramov elasomerana.
_ _
3.
SEZNAM POMOŽNIH SNOVI
Pomožne snovi: SM-102, holesterol,
1,2-distearoil-sn-glicero-3
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo
hitreje na voljo nove informacije
o njegovi varnosti. Zdravstvene delavce naprošamo, da poročajo o
katerem koli domnevnem
neželenem učinku zdravila. Glejte poglavje 4.8, kako poročati o
neželenih učinkih.
1.
IME ZDRAVILA
Spikevax 0,2 mg/ml disperzija za injiciranje
Spikevax 0,1 mg/ml disperzija za injiciranje
Spikevax 50 mikrogramov disperzija za injiciranje v napolnjeni
injekcijski brizgi
mRNK cepivo proti COVID-19
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
PREGLEDNICA 1. KAKOVOSTNA IN KOLIČINSKA SESTAVA GLEDE NA JAKOST IN
VRSTO VSEBNIKA
JAKOST
VSEBNIK
ODMEREK(I)
SESTAVA ODMERKA
SPIKEVAX
0,2 MG/ML
DISPERZIJA ZA
INJICIRANJE
večodmerna
viala (rdeča
odstranljiva
zaporka)
največ 10 odmerkov,
vsak po 0,5 ml
En odmerek (0,5 ml) vsebuje
100 mikrogramov elasomerana,
cepiva proti COVID-19 na osnovi
mRNK (s spremenjenimi
nukleozidi) (vgrajene v lipidne
nanodelce).
največ 20 odmerkov,
vsak po 0,25 ml
En odmerek (0,25 ml) vsebuje
50 mikrogramov elasomerana,
cepiva proti COVID-19 na osnovi
mRNK (s spremenjenimi
nukleozidi) (vgrajene v lipidne
nanodelce).
SPIKEVAX
0,1 MG/ML
DISPERZIJA ZA
INJICIRANJE
večodmerna
viala (modra
odstranljiva
zaporka)
5 odmerkov,
vsak po 0,5 ml
En odmerek (0,5 ml) vsebuje
50 mikrogramov elasomerana,
cepiva proti COVID-19 na osnovi
mRNK (s spremenjenimi
nukleozidi) (vgrajene v lipidne
nanodelce).
največ 10 odmerkov,
vsak po 0,25 ml
En odmerek (0,25 ml) vsebuje
25 mikrogramov elasomerana,
cepiva proti COVID-19 na osnovi
mRNK (s spremenjenimi
nukleozidi) (vgrajene v lipidne
nanodelce).
SPIKEVAX
50 MIKROGRAMOV
DISPERZIJA ZA
INJICIRANJE V
NAPOLNJENI
INJEKCIJSKI
BRIZGI
napolnjena
injekcijska
brizga
1 odmerek po 0,5 ml
Samo za enkratno
uporabo.
Napolnjene
injekcijske brizge ne
uporabljajte za
dajanje delnega
volumna 0,25 ml.
En odmerek (0,5 ml) vsebuje
50 mikrogramov elasomerana,
cepiva proti COVID-19 na osnovi
mRNK (s spremenjenimi
nukleozidi) (vgrajene v lipidne
nanodelce).
3
Elas
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 01-02-2024
Public Assessment Report Public Assessment Report Bulgarian 28-09-2023
Patient Information leaflet Patient Information leaflet Spanish 01-02-2024
Public Assessment Report Public Assessment Report Spanish 28-09-2023
Patient Information leaflet Patient Information leaflet Czech 01-02-2024
Public Assessment Report Public Assessment Report Czech 28-09-2023
Patient Information leaflet Patient Information leaflet Danish 01-02-2024
Public Assessment Report Public Assessment Report Danish 28-09-2023
Patient Information leaflet Patient Information leaflet German 01-02-2024
Public Assessment Report Public Assessment Report German 28-09-2023
Patient Information leaflet Patient Information leaflet Estonian 01-02-2024
Public Assessment Report Public Assessment Report Estonian 28-09-2023
Patient Information leaflet Patient Information leaflet Greek 01-02-2024
Public Assessment Report Public Assessment Report Greek 28-09-2023
Patient Information leaflet Patient Information leaflet English 01-02-2024
Public Assessment Report Public Assessment Report English 28-09-2023
Patient Information leaflet Patient Information leaflet French 01-02-2024
Public Assessment Report Public Assessment Report French 28-09-2023
Patient Information leaflet Patient Information leaflet Italian 01-02-2024
Public Assessment Report Public Assessment Report Italian 28-09-2023
Patient Information leaflet Patient Information leaflet Latvian 01-02-2024
Public Assessment Report Public Assessment Report Latvian 28-09-2023
Patient Information leaflet Patient Information leaflet Lithuanian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-02-2024
Public Assessment Report Public Assessment Report Lithuanian 28-09-2023
Patient Information leaflet Patient Information leaflet Hungarian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 01-02-2024
Public Assessment Report Public Assessment Report Hungarian 28-09-2023
Patient Information leaflet Patient Information leaflet Maltese 01-02-2024
Public Assessment Report Public Assessment Report Maltese 28-09-2023
Patient Information leaflet Patient Information leaflet Dutch 01-02-2024
Public Assessment Report Public Assessment Report Dutch 28-09-2023
Patient Information leaflet Patient Information leaflet Polish 01-02-2024
Public Assessment Report Public Assessment Report Polish 28-09-2023
Patient Information leaflet Patient Information leaflet Portuguese 01-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 01-02-2024
Public Assessment Report Public Assessment Report Portuguese 28-09-2023
Patient Information leaflet Patient Information leaflet Romanian 01-02-2024
Public Assessment Report Public Assessment Report Romanian 28-09-2023
Patient Information leaflet Patient Information leaflet Slovak 01-02-2024
Public Assessment Report Public Assessment Report Slovak 28-09-2023
Patient Information leaflet Patient Information leaflet Finnish 01-02-2024
Public Assessment Report Public Assessment Report Finnish 28-09-2023
Patient Information leaflet Patient Information leaflet Swedish 01-02-2024
Public Assessment Report Public Assessment Report Swedish 28-09-2023
Patient Information leaflet Patient Information leaflet Norwegian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 01-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 01-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 01-02-2024
Patient Information leaflet Patient Information leaflet Croatian 01-02-2024
Public Assessment Report Public Assessment Report Croatian 28-09-2023